- Home
- SFD vs AXSM Comparison
SFD vs AXSM Comparison
Compare SFD & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFD
- AXSM
- Stock Information
- Founded
- SFD 1936
- AXSM 2012
- Country
- SFD United States
- AXSM United States
- Employees
- SFD N/A
- AXSM N/A
- Industry
- SFD
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- SFD
- AXSM Health Care
- Exchange
- SFD NYSE
- AXSM Nasdaq
- Market Cap
- SFD 7.4B
- AXSM 6.2B
- IPO Year
- SFD 2025
- AXSM 2015
- Fundamental
- Price
- SFD $19.33
- AXSM $119.45
- Analyst Decision
- SFD Strong Buy
- AXSM Strong Buy
- Analyst Count
- SFD 5
- AXSM 14
- Target Price
- SFD $28.60
- AXSM $168.64
- AVG Volume (30 Days)
- SFD 591.0K
- AXSM 915.7K
- Earning Date
- SFD 01-01-0001
- AXSM 05-05-2025
- Dividend Yield
- SFD N/A
- AXSM N/A
- EPS Growth
- SFD 14.48
- AXSM N/A
- EPS
- SFD 1.72
- AXSM N/A
- Revenue
- SFD $14,188,000,000.00
- AXSM $385,693,000.00
- Revenue This Year
- SFD N/A
- AXSM $65.06
- Revenue Next Year
- SFD N/A
- AXSM $63.84
- P/E Ratio
- SFD $11.25
- AXSM N/A
- Revenue Growth
- SFD N/A
- AXSM 42.53
- 52 Week Low
- SFD $18.43
- AXSM $64.11
- 52 Week High
- SFD $22.03
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- SFD N/A
- AXSM 48.15
- Support Level
- SFD N/A
- AXSM $116.00
- Resistance Level
- SFD N/A
- AXSM $128.43
- Average True Range (ATR)
- SFD 0.00
- AXSM 5.08
- MACD
- SFD 0.00
- AXSM -2.27
- Stochastic Oscillator
- SFD 0.00
- AXSM 14.92
About SFD SMITHFIELD FOODS INC
Smithfield is the largest hog producer and pork processor in the world, processing more than 27 million hogs in fiscal 2011, with a slaughter capacity of 110,000 hogs per day. Around 55% of all pork revenue comes from value-added packaged meats, which were the focus of previous acquisitions and central to the company's long-term strategy. The firm continues to expand its European operations.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.